Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q3 2023
Holdings as of Sep 30, 2023, filed Nov 14, 2023. Long positions only; changes compare share counts with Q2 2023.
- Positions
- 30
- +4 vs. Q2 2023
- Portfolio value
- $855.5M
- −$34.3M (−3.9%) vs. Q2 2023
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| DBVTDBV Technologies S.A. | SPONSORED ADR | 92,687 | $126.1K | <0.1% | 00.0% | Unchanged | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 116,324 | $1.42M | 0.2% | 00.0% | UnchangedConverted for a 1-for-25 split | History |
| MRSNMersana Therapeutics, Inc. | COM | 2,244,378 | $2.85M | 0.3% | +2,244,378 | New | History |
| APGEApogee Therapeutics, Inc. | COM | 250,000 | $5.33M | 0.6% | +250,000 | New | History |
| RYZBRayzeBio, Inc. | COM | 288,911 | $6.41M | 0.7% | +288,911 | New | History |
| VTGNVistagen Therapeutics, Inc. | COM | 1,575,000 | $8.25M | 1.0% | +1,575,000 | New | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 739,661 | $9.08M | 1.1% | 00.0% | Unchanged | History |
| THRDThird Harmonic Bio, Inc. | COM | 1,700,000 | $10.9M | 1.3% | +706,706+71.1% | Added | History |
| KURAKura Oncology, Inc. | COM | 1,400,000 | $12.8M | 1.5% | 00.0% | Unchanged | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 957,509 | $13.9M | 1.6% | −40,087−4.0% | Reduced | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 500,000 | $14.9M | 1.7% | +500,000 | New | History |
| ADVMAdverum Biotechnologies, Inc. | COM | 10,000,000 | $15.0M | 1.8% | 00.0% | Unchanged | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 1,325,000 | $15.2M | 1.8% | 00.0% | Unchanged | History |
| CELCCelcuity Inc. | COM | 1,694,141 | $15.5M | 1.8% | +250,000+17.3% | Added | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 706,665 | $19.4M | 2.3% | +75,000+11.9% | Added | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 775,000 | $20.9M | 2.4% | 00.0% | Unchanged | History |
| SLNOSoleno Therapeutics Inc | COM | 887,500 | $26.2M | 3.1% | +887,500 | New | History |
| AKROAkero Therapeutics, Inc. | COM | 565,000 | $28.6M | 3.3% | −1,110,000−66.3% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 2,200,000 | $33.7M | 3.9% | 00.0% | Unchanged | History |
| NUVLNuvalent, Inc. | COM | 828,778 | $38.1M | 4.5% | −321,222−27.9% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 1,000,000 | $38.4M | 4.5% | +100,000+11.1% | Added | History |
| CABACabaletta Bio, Inc. | COM | 2,525,753 | $38.4M | 4.5% | +157,567+6.7% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 2,901,816 | $39.6M | 4.6% | +553,544+23.6% | Added | History |
| AMAMAmbrx Biopharma Cayman, Inc. | SPONSORED ADS | 3,518,556 | $40.5M | 4.7% | +343,556+10.8% | Added | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 2,075,000 | $47.6M | 5.6% | +2,075,000 | New | History |
| COGTCogent Biosciences, Inc. | COM | 5,566,026 | $54.3M | 6.3% | 00.0% | Unchanged | History |
| PCVXVaxcyte, Inc. | COM | 1,100,000 | $56.1M | 6.6% | +85,000+8.4% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 1,845,000 | $63.0M | 7.4% | 00.0% | Unchanged | History |
| VERAVera Therapeutics, Inc. | CL A | 5,450,000 | $74.7M | 8.7% | 00.0% | Unchanged | History |
| MRUSMerus N.V. | COM | 4,428,072 | $104.4M | 12.2% | +428,072+10.7% | Added | History |
Sold out since Q2 2023 (3)
Positions held at the end of Q2 2023 that are gone from this filing.
| Security | Class | Shares in Q2 2023 | Value in Q2 2023 | % of portfolio in Q2 2023 | History |
|---|---|---|---|---|---|
| CBAYCymaBay Therapeutics, Inc. | COM | 2,025,000 | $22.2M | 2.5% | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 610,000 | $21.8M | 2.4% | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 312,553 | $2.81M | 0.3% | History |